The US Food and Drug Administration has authorised a robot that removes bladder tumours through the urethra using two arms about a millimetre thick, and in doing so created a new category of medical device. Virtuoso Surgical, a company founded out of Vanderbilt University, says the FDA granted De Novo authorisation for its Virtuoso Endoscopy System on 30 October. It announced the decision on 10 November.
The system puts two needle-sized arms, made of flexible nitinol tubes, at the tip of a rigid endoscope. A surgeon at a console controls both: one arm lifts the tumour while the other cuts beneath it, so it comes out in one piece (en bloc) rather than in scraps. That matters because doctors need the muscle layer under a tumour to judge how far a cancer has spread. The robot does not act on its own.
In an early study at Prince of Wales Hospital in Hong Kong, all 12 lesions in 6 patients were removed in one piece, with muscle present in every sample. Across the first 20 patients, the company reports muscle in 94% of lesions, which it calls preliminary, single-site data. The company plans a focused US launch at urology centres in 2027.
De Novo is the FDA route for device types with no existing equivalent, so later rivals now have a category to follow. See our explainer How do robots learn? for how surgeon-controlled and autonomous robots differ.
Virtuoso Surgical announcement; CancerNetwork; Urology Times.




